We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

36 hedge funds and large institutions have $4.53M invested in Aspire Biopharma Warrant in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

54% more capital invested

Capital invested by funds: $2.94M → $4.53M (+$1.58M)

0% more funds holding

Funds holding: 36 → 36 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

Holders
36
Holders Change
–
Holders Change %
0%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
1
Closed
5
Calls
$2.11M
Puts
–
Net Calls
+$2.11M
Net Calls Change
+$14K

Top Buyers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
+$32.9K
2
LP
LMR Partners
United Kingdom
+$8.4K
3
MP
Mangrove Partners
Connecticut
+$4.35K
4
AC
Athos Capital
Hong Kong
+$1.68K
5
OAC
OMERS Administration Corp
Ontario, Canada
+$1.68K

Top Sellers

Rank Fund Capital Flow
1
MF
Magnetar Financial
Illinois
-$29K
2
BCM
Basso Capital Management
Connecticut
-$6K
3
KKRC
Kohlberg Kravis Roberts & Co
New York
-$3K
4
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
-$1K
5
CH
CVI Holdings
Delaware
-$27
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$1.69M – – –
LP
2
LMR Partners
United Kingdom
$1.29M +$8.4K +125,000 New
MP
3
Mangrove Partners
Connecticut
$666K +$4.35K +64,705 New
AC
4
Athos Capital
Hong Kong
$257K +$1.68K +24,999 New
PC
5
Periscope Capital
Ontario, Canada
$87.9K +$32.9K +489,865 +52%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$83.9K – – –
AA
7
AQR Arbitrage
Connecticut
$53.6K – – –
SCM
8
Saba Capital Management
New York
$40K – – –
LA
9
Linden Advisors
New York
$36.6K – – –
Verition Fund Management
10
Verition Fund Management
Connecticut
$34.6K – – –
WAM
11
Wolverine Asset Management
Illinois
$32.1K – – –
KC
12
Kepos Capital
New York
$28K – – –
Barclays
13
Barclays
United Kingdom
$28K – – –
TCA
14
Taconic Capital Advisors
New York
$24K – – –
SC
15
Sculptor Capital
New York
$20.3K – – –
Balyasny Asset Management
16
Balyasny Asset Management
Illinois
$16K – – –
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$16K – – –
CCM
18
Context Capital Management
California
$14K – – –
SRCM
19
Sage Rock Capital Management
New York
$12.8K – – –
CS
20
Clear Street
New York
$12K +$418 +6,227 +4%
PAMP
21
Polar Asset Management Partners
Ontario, Canada
$11.1K – – –
HCM
22
Highbridge Capital Management
New York
$11K – – –
Nomura Holdings
23
Nomura Holdings
Japan
$11K – – –
WA
24
Whitebox Advisors
Minnesota
$9.99K – – –
KL
25
KIM LLC
Kansas
$8K – – –
1
2

ASBPW Hedge Fund Activity: Q4 2022 in Review

36 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q4 2022, worth a combined $4.53M — up 54% from $2.94M a quarter earlier.

Fund positioning in ASBPW was balanced in Q4 2022: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Periscope Capital, adding an estimated $32.9K. The largest seller was Magnetar Financial, exiting entirely with an estimated $29K sold.

  • 36 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $4.53M of Aspire Biopharma Warrant stock for Q4 2022, up 54% quarter-over-quarter.
  • 5 funds opened new Aspire Biopharma Warrant positions in Q4 2022 and 5 closed out, a net change of 0 holders.
  • The largest Aspire Biopharma Warrant buyer in Q4 2022 was Periscope Capital, an estimated $32.9K added.
  • The largest Aspire Biopharma Warrant seller in Q4 2022 was Magnetar Financial, an estimated $29K sold.

Based on aggregated 13F filings for Q4 2022.